Capitalism is criticized as both the cause of, and the main barrier to, effective mitigation of climate change. Yet, from the earliest days of the international negotiations, states have agreed that technological innovation, believed to be a primary strength of capitalism, is crucial to prevention of a dangerous accumulation of atmospheric greenhouse gases. Nations prefer to rely on innovative technologies to reduce emissions than to use regulations to constrain markets and limit social choice. The contributors to this volume show that the strengths of the system that creates ever new consumer products and industrial processes actually prevent the generation of technological innovations that would most effectively mitigate climate change. Through comprehensive research of the US innovation system and how companies respond to its supporting institutions, they demonstrate that liberal capitalism's perceived strengths are also its weaknesses. They also show that current theories of technological innovation are incomplete and suggest the institutional changes needed to generate climate innovations.

Capitalism is criticized as both the cause of, and the main barrier to, effective mitigation of climate change. Yet, from the earliest days of the international negotiations, states have agreed that technological innovation, believed to be a primary strength of capitalism, is crucial to prevention of a dangerous accumulation of atmospheric greenhouse gases. Nations prefer to rely on innovative technologies to reduce emissions than to use regulations to constrain markets and limit social choice. The contributors to this volume show that the strengths of the system that creates ever new consumer products and industrial processes actually prevent the generation of technological innovations that would most effectively mitigate climate change. Through comprehensive research of the US innovation system and how companies respond to its supporting institutions, they demonstrate that liberal capitalism's perceived strengths are also its weaknesses. They also show that current theories of technological innovation are incomplete and suggest the institutional changes needed to generate climate innovations.

This is a concise, practical, case-based book documenting examples and scenarios that will help you manage challenging clinical issues for patients with myeloproliferative neoplasms. The editors and authors have strived to distil the very latest information in this rapidly advancing field in a way that will help you to update your practice and manage your patients. The key focuses are: diagnosis, both standard and challenging; both day-to-day management as well as special situations such as surgery, thrombotic events and pregnancy; and finally, managing evolving situations with MPN such as progression to acute myeloid leukemia. This book is an outstanding resource that includes a discussion of both classical myeloproliferative neoplasms, such as essential thrombocythemia, polycythemia vera and myelofibrosis, and also less common disorders such as systemic mast cell disease, hypereosinophilia, MPN/MBS overlap syndromes and atypical CML, amongst others. This book is a practical reference for practitioners, hematologists, medical oncologists and trainees.